Stifel raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $90 and keeps a Buy rating on the shares. The TAVR performance in Q2 is “the best since 2023 and an encouraging indicator that the EARLY TAVR data is positively impacting physician utilization,” the analyst tells investors in a post-earnings note. Recent physician conversations and wider-ranging due diligence have “repeatedly pointed to EARLY TAVR providing a positive halo effect” on Edwards’ TAVR growth, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $80 from $77 at Evercore ISI
- Edwards Lifesciences price target raised to $79 from $78 at Baird
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Edwards Lifesciences price target raised to $94 from $85 at Deutsche Bank